A single-center study demonstrated the efficacy and safety of a combined treatment with anti-CD19 CAR T cells and the anti-PD-1 antibody nivolumab in 11 patients with r/r B cell NHL [80]. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.